OncoMatch/Clinical Trials/NCT07186842
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Is NCT07186842 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including BNT329 and CA19-9-targeting monoclonal antibody for advanced solid cancers.
Treatment: BNT329 · CA19-9-targeting monoclonal antibody — The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Cholangiocarcinoma
Urothelial Carcinoma
Colorectal Cancer
Esophageal Carcinoma
Gastric Cancer
Endometrial Cancer
Ovarian Cancer
Biomarker criteria
Required: CA19-9 expression (testing required; no eligibility threshold specified)
advanced/metastatic tumor type that is known to express CA19-9
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Participants must have received all available standard therapies, including targeted therapies based on mutation status (per guidelines...), and failed at least first-line standard of care therapy prior to enrollment
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SCRI at HCA Health One · Denver, Colorado
- Florida Cancer Specialists · Orlando, Florida
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07186842 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Does this trial require CA19-9?
Yes, CA19-9 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages